rs1884613 — HNF4A HNF4A P2 Promoter T2D Variant

Intronic variant tagging the HNF4A P2 promoter risk haplotype; the G allele strongly elevates type 2 diabetes risk in Ashkenazi Jewish populations (OR ~1.70) and modestly in Scandinavians (OR ~1.14) by reducing beta-cell-specific HNF4A isoform expression

Moderate Risk Factor Share

Details

Gene: HNF4A
Chromosome: 20
Risk allele: G
Clinical: Risk Factor
Evidence: Moderate

Population Frequency

66%

30%

External

SNPedia ClinVar dbSNP

See your personal result for HNF4A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HNF4A P2 Promoter — The Population-Specific Beta-Cell Diabetes Switch

HNF4A¹¹ HNF4A
Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor that controls dozens of metabolic genes in liver, intestine, kidney, and pancreatic beta cells is one of the master regulators of glucose and lipid homeostasis. It has a unique dual-promoter architecture: P1 drives the adult-liver isoform, while the P2 promoter²² P2 promoter
Located approximately 46 kb upstream of P1, the P2 promoter is active specifically in pancreatic beta cells and the fetal liver. Essentially all beta-cell HNF4A expression derives from P2-driven transcripts — making this promoter region critical for pancreatic function while being largely irrelevant to hepatic HNF4A activity. drives the "beta-cell-specific" isoform (HNF4A7–12). rs1884613 is an intronic variant that falls within the P2 haplotype block — a cluster of highly correlated SNPs tagging the P2 promoter risk haplotype. Rare P2 mutations that inactivate HNF4A cause MODY1³³ MODY1
Maturity-Onset Diabetes of the Young type 1 — an autosomal dominant, early-onset monogenic diabetes arising from HNF4A haploinsufficiency in beta cells. rs1884613 is not a MODY mutation, but it operates along the same biological axis at vastly smaller effect sizes.

The Mechanism

The P2 promoter drives HNF4A isoforms that regulate a suite of genes essential for glucose-stimulated insulin secretion — including glucokinase (the islet glucose sensor), the Kir6.2 subunit of the ATP-sensitive potassium channel, and the insulin gene itself. The G allele at rs1884613 is in near-perfect LD (r²≈0.99) with rs2144908 and marks carriers of a P2 haplotype associated with subtly reduced P2 promoter activity and lower HNF4A expression in pancreatic beta cells. Less HNF4A means quieter insulin secretion signaling, which over years accumulates into impaired glucose tolerance and type 2 diabetes susceptibility.

In established type 2 diabetes, the HNF4A P2 isoform becomes aberrantly re-expressed in adult liver⁴⁴ aberrantly re-expressed in adult liver
Glucagon (chronically elevated in T2D) activates TET3, which demethylates the P2 promoter. FOXA2 then drives P2 transcription in hepatocytes, causing the fetal HNF4A isoform to stimulate excessive hepatic glucose output — a feed-forward loop worsening hyperglycemia. The P2 risk haplotype may predispose to this aberrant hepatic re-activation under metabolic stress, compounding both impaired beta-cell secretion and excess hepatic glucose production.

The Evidence

The HNF4A P2 haplotype was first linked to T2D in 2004 when Weedon et al.⁵⁵ Weedon et al.
Weedon MN et al. Common variants of the hepatocyte nuclear factor 4-alpha P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes 2004. PMID:15504983 identified rs1884613 among four P2 region variants associated with T2D in 5,256 UK subjects (risk haplotype OR 1.15, 95% CI 1.02–1.33). A 2007 Scandinavian meta-analysis by Johansson et al.⁶⁶ Johansson et al.
Johansson S et al. Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the HNF4A P2 region are associated with type 2 diabetes in Scandinavians. Diabetes 2007. PMID:17827402 confirmed the signal with OR 1.14 (95% CI 1.06–1.23, P=0.0004) across 4,000 Norwegian cases and 7,571 controls.

The most striking finding emerged from the Barroso et al. 2008 population comparison⁷⁷ Barroso et al. 2008 population comparison
Barroso I et al. Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. Diabetes 2008. PMID:18728231: rs1884613 showed OR ~1.7 in Ashkenazi Jewish subjects (n=991; P<1.6×10⁻⁶) but only OR 1.04 (non-significant) in UK populations (n=4,022). This dramatic difference at nearly identical G allele frequencies (~17–23%) implies the causal variant within the P2 haplotype block is in closer LD with rs1884613 in Ashkenazi Jewish ancestry due to extended founder-effect haplotype structure.

The Ashkenazi signal was independently confirmed by Neuman et al. 2010⁸⁸ Neuman et al. 2010
Neuman RJ et al. Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population. PLoS One 2010. PMID:20361036 in 974 cases and 896 controls: rs1884613 gave unadjusted OR 1.69 (95% CI 1.40–2.03, P<0.0001) and adjusted OR 1.77 (95% CI 1.39–2.24). Critically, gene-gene interaction analyses revealed that carriers of both rs1884613 G and WFS1 rs10010131 risk alleles had OR 3.0 (95% CI 1.7–5.3) for T2D, and carriers of both HNF4A and TCF7L2 rs12255372 risk alleles had OR 2.4 (95% CI 1.7–3.4) — demonstrating that HNF4A P2 haplotype risk is substantially amplified by co-occurring beta-cell stressors.

Practical Actions

Because the primary risk mechanism is impaired HNF4A-driven beta-cell insulin secretion, the most actionable dietary lever is reducing the insulin secretory demand placed on pancreatic beta cells — specifically choosing lower-glycemic-load carbohydrates (legumes, intact grains, non-starchy vegetables) over rapidly absorbed refined starches that demand peak insulin secretory responses. Periodic monitoring of fasting glucose and HbA1c allows early detection of declining beta-cell reserve. For Ashkenazi Jewish individuals carrying the G allele, the ~1.7-fold per-allele risk estimate is clinically meaningful and warrants more proactive surveillance than for non-Ashkenazi Europeans where the effect is modest (~OR 1.14).

Interactions

rs1884613 and rs2144908 are in near-perfect LD (r²=0.99) and tag the same P2 haplotype signal — they cannot be separated in published studies. Other P2 haplotype tags (rs4810424, rs1884614, rs6031552) probe the same signal with varying LD. rs4812829 is in a different HNF4A intronic LD block and represents an independent GWAS signal in South Asians; carrying risk alleles at both rs1884613 and rs4812829 would represent additive, not correlated, HNF4A-linked risk.

The Neuman 2010 gene-gene interaction data identifies WFS1 rs10010131 (beta-cell ER homeostasis) and TCF7L2 rs12255372 (Wnt-driven incretin signaling) as the two most important interacting variants. The WFS1 interaction (OR 3.0) is especially notable because WFS1/wolframin controls ER calcium handling in beta cells — an independent beta-cell stress mechanism that synergizes with transcriptional HNF4A deficiency.

Nutrient Interactions

glucose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

CC “Common Genotype” Normal

Reference genotype — no elevated T2D risk from this HNF4A P2 variant

You carry two copies of the C allele, the GRCh38 reference sequence at rs1884613. This is the most common genotype globally, present in approximately 66% of people (rising to ~70% in Europeans). You do not carry the G allele that tags the HNF4A P2 promoter risk haplotype, so your HNF4A-driven beta-cell insulin secretory capacity is unaffected at this locus and your type 2 diabetes risk from rs1884613 is at the population baseline.

The C allele frequency is highest in African populations (~90%) and lower in East Asian (~55%) and Latino (~62%) populations, where the G risk allele is more prevalent.

CG “P2 Haplotype Carrier” Intermediate Caution

One copy of the HNF4A P2 risk haplotype — elevated T2D risk, especially in Ashkenazi ancestry

The population-specificity of this variant is critical context. In Ashkenazi Jewish individuals, the G allele tags the true P2 causal variant more faithfully — likely due to the extended founder-effect haplotype in this population — yielding OR ~1.7 that is clinically actionable. In non-Ashkenazi Europeans, the same G allele tags the haplotype with weaker LD to the causal variant, producing OR ~1.14 in Scandinavians and a non-significant effect in UK populations (Barroso 2008).

The Neuman 2010 study found that Ashkenazi CG carriers who also carry WFS1 rs10010131 risk alleles face OR 3.0 for T2D — illustrating that the P2 haplotype risk is amplified by co-occurring beta-cell stress. Monitoring is particularly important for CG carriers with additional T2D risk factors (family history, elevated fasting glucose, or risk alleles at WFS1 or TCF7L2).

GG “P2 Haplotype Homozygote” High Risk Warning

Two copies of the HNF4A P2 risk haplotype — highest T2D susceptibility at this locus

With two G alleles, both copies of the HNF4A P2 promoter in pancreatic beta cells carry the risk haplotype. This biallelic configuration reduces HNF4A-driven gene expression in islets more substantially than a single copy, affecting glucokinase activity, insulin gene transcription, and KATP channel subunit expression that gates insulin release. The resulting deficit in glucose-stimulated insulin secretion is the same mechanism — just at greater allele dosage — as the one that causes MODY1 when HNF4A is lost entirely from one chromosome.

Unlike insulin resistance (where the pancreas initially compensates by secreting more insulin), this is a secretory capacity deficit. Fasting glucose may rise gradually as beta-cell reserve depletes without the preceding hyperinsulinemia typical of early T2D. The standard prediabetes screen (fasting glucose) may not catch early HNF4A-mediated secretory dysfunction — an OGTT, which specifically challenges beta-cell secretory capacity, is more sensitive.

The Neuman 2010 study found that Ashkenazi carriers of both HNF4A and WFS1 risk alleles had OR 3.0 for T2D. For GG homozygotes who also carry WFS1 risk alleles, the combination of biallelic P2 haplotype dosage plus ER calcium stress is a high-risk profile warranting clinical discussion.